A Phase 3, multicenter, randomized, open-label, active-controlled study of DS-8201a, an anti-HER2-antibody drug conjugate, versus treatment of investigator’s choice for HER2-positive, unresectable and/or metastatic breast cancer subjects pretreated with prior standard of care HER2 therapies, including T-DM1

  • Kefford, Richard (Primary Chief Investigator)
  • Butala, Radhika (Associate Investigator)
  • Cunningham, Jacob (Associate Investigator)

Project: Other

Project Details

Short titleDS8201-A-U301
Effective start/end date12/03/1925/11/23